Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed) | PAR 20 082

Opportunity Information: Apply for PAR 20 082

Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed) is a National Institutes of Health (NIH) grant opportunity (PAR-20-082) that funds early-stage, exploratory research aimed at building better lab-based models of the human nervous system. The focus is on next-generation microphysiological systems (MPS), meaning advanced, human cell-derived platforms (often organ-on-a-chip style systems, 3D cultures, or integrated microengineered tissues) that can reproduce the structure and function of nervous system tissues more realistically than today s common models. The goal is not simply to create another neural culture, but to engineer systems that capture complex nervous system architecture and physiology with higher fidelity, so they can be used later to study how the nervous system develops, works, ages, and changes in disease.

Projects supported under this announcement are expected to push beyond current capabilities by incorporating features that make nervous system models more life-like and more informative. That can include more accurate cellular diversity (multiple neuronal and glial subtypes, for example), more realistic organization (layering, regional patterning, tract-like connectivity, or circuit-level behavior), and functional readouts that reflect true physiology rather than limited proxy signals. The FOA also explicitly mentions related assays, which signals that NIH is interested not only in the physical MPS platform, but also in the measurement approaches that allow researchers to quantify function, maturation, degeneration, or responses to perturbations in a reliable, scalable way. In practice, this could involve electrophysiology, imaging-based functional assays, transcriptomic or proteomic profiling, or other methods that help demonstrate that the engineered system behaves like human nervous tissue.

A key point is that these projects are framed as enabling tools for future research rather than full-scale disease studies right away. NIH is looking for platforms that will make it possible to study complex nervous system development, function, and aging in both healthy and disease states down the road. In other words, the grant is meant to support the engineering and validation of the model system itself (and the assays that go with it), so that later studies can use those systems to ask deeper biological or translational questions. The mechanism is R21, which typically supports exploratory, higher-risk work where strong preliminary data may be limited, but the potential payoff in capability is high. Clinical trials are not allowed under this announcement, which means applicants should not propose studies that assign human participants to interventions to evaluate health outcomes; the work should remain preclinical, model-based, and focused on MPS development and testing.

The opportunity is categorized as a discretionary grant in the education and health activity area and is associated with multiple CFDA numbers (93.173, 93.242, 93.279, 93.853, 93.866, 93.867), reflecting NIH s cross-institute interest in nervous system biology, neurological disorders, and enabling technologies. The listing does not provide an award ceiling or expected number of awards in the provided data, so applicants would typically look to the full FOA text and NIH standard R21 budget guidance for practical expectations around project scope and funding level.

Eligibility is broad and includes many common applicant types, such as public and private institutions of higher education, state and local governments, independent school districts, special district governments, federally recognized Native American tribal governments, and various nonprofit organizations (both 501(c)(3) and non-501(c)(3)). It also allows for for-profit organizations (other than small businesses) and small businesses, as well as certain housing authorities and other organizational categories. Importantly, the FOA also highlights additional eligible applicants that NIH explicitly welcomes, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, and eligible federal agencies. It further notes that non-U.S. entities (foreign organizations), regional organizations, U.S. territories or possessions, and Indian/Native American tribal governments that are not federally recognized may also be eligible, which expands participation beyond the standard domestic academic applicant pool.

In terms of timing, the source data shows a creation date of 2020-01-03 and an original closing date listed as 2023-01-07. Since deadlines and re-issuances can change over time, anyone planning to apply would normally confirm the current status in NIH systems or the active FOA page, but the provided record indicates the opportunity was active across multiple years.

Overall, this FOA is designed for teams that can combine human cell biology with bioengineering, microfabrication, and robust functional testing to produce nervous system MPS platforms that are more structurally and functionally authentic. The strongest fits are proposals that clearly identify what limitation in current nervous system models they are overcoming, what engineering and biological innovations they are introducing, and how they will demonstrate improved fidelity using well-justified assays and benchmarks, all while staying firmly on the preclinical side (no clinical trials).

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173, 93.242, 93.279, 93.853, 93.866, 93.867.
• This funding opportunity was created on 2020-01-03.
• Applicants must submit their applications by 2023-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 20 082

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: